Trentilin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trentilin

Quick Facts

Property Description
Active ingredient Pentoxifylline
Form Extended-release tablet, solution for injection
Pharmacological class Hemorrheologic Agent; Methylxanthine Derivative
Common use Circulatory support
Origin Synthetic compound

What is Pentoxifylline, the Active Ingredient in Trentilin?

Trentilin is a synthetic, single-ingredient, prescription medicine that contains the active substance Pentoxifylline, a compound chemically classified as a derivative of the methylxanthine group.

The medication is specifically categorized as a hemorrheologic agent, a designation that places it among circulatory system modifiers. This classification confirms that the drug’s primary function is to modify the physical properties of the blood, distinguishing it from simple vasodilators. Pentoxifylline is clinically recognized for its role in improving blood flow in certain conditions.

What Type of Medicine is Trentilin?

Trentilin functions as a rheologic modifier with the general purpose of optimizing the quality and ease of blood flow, particularly through the microcirculation. It achieves this by decreasing the overall thickness or viscosity of the blood and simultaneously enhancing the flexibility of red blood cells.

This dual mechanism is crucial because it allows the red blood cells, which transport oxygen, to deform and pass through narrow or partially blocked capillaries more efficiently. By supporting blood fluidity, the drug aims to facilitate more sustained delivery of oxygen and nutrients to tissues throughout the body, providing essential circulatory support.

What are the Available Forms of Trentilin?

As a systemic medication, Trentilin is primarily provided in two main pharmaceutical preparations for controlled administration: an extended-release tablet for oral administration and a sterile solution for injection in ampoules for parenteral use.

The extended-release tablet form is a unique characteristic, specifically formulated to gradually release the Pentoxifylline over an extended duration. This design is intended to sustain the therapeutic hemorrheologic effect over time, allowing medical providers to determine the appropriate route of administration based on the patient’s clinical need for sustained or more immediate circulatory modification.

What side effects are possible with Trentilin?

Possible Side Effects and Safety Information

The safety profile of Trentilin (pentoxifylline) is derived from clinical trials and official postmarketing surveillance, classifying adverse reactions by frequency and the organ system affected. The most frequently documented side effects involve the Gastrointestinal and Nervous Systems.

Official Adverse Reactions

Side effects that are generally classified as Most Frequent (Common) include abdominal discomfort, nausea, vomiting, dizziness, and headache. Less common reactions have included flushing, dyspepsia, and tremor.

System-Organ Class (SOC) Examples of Officially Listed Reactions
Gastrointestinal Nausea, Vomiting, Diarrhea, Abdominal Pain
Nervous System Dizziness, Headache, Insomnia, Tremor
Cardiovascular Flushing, Arrhythmia, Hypotension

Serious Safety Considerations

Regulatory documentation highlights the potential for bleeding events as a significant safety consideration, especially with concomitant use of other agents that affect blood clotting. Rare, but serious, reactions reported primarily in postmarketing surveillance include severe hypersensitivity reactions like Anaphylaxis and hematologic disorders such as Aplastic Anemia.

Population-Specific Notes and Restrictions

Safety is formally constrained by pre-existing conditions. Trentilin is contraindicated in individuals with a history of recent cerebral or retinal hemorrhage and in those with known intolerance to methylxanthine derivatives (such as theophylline or caffeine). Additionally, official labels advise caution for patients with renal impairment, as reduced drug clearance may increase the risk of toxic reactions. The drug is generally not recommended for use in severe hepatic impairment.

Overdose and Emergency Response

Trentilin overdose is a serious medical event documented in official prescribing information, defined by severe manifestations affecting the cardiovascular and central nervous systems. Initial signs of overdose may include nausea, dizziness, rapid heart rate (tachycardia), and a significant fall in blood pressure (hypotension). As the event progresses, documented symptoms can escalate to include fever (hyperthermia), physical agitation, and the absence of reflexes (areflexia).

Regulators mandate that individuals seek immediate medical attention for any suspected overdose scenario. Severe or life-threatening outcomes reported in regulatory documents include the development of tonic-clonic convulsions (seizures), complete loss of consciousness, and coffee-ground vomiting, which is indicative of potential gastrointestinal bleeding.

In managing an overdose, regulatory documents state that no specific antidote is known. Therefore, management procedures focus on supportive and symptomatic treatment, with a specific emphasis on continuous support for the cardiovascular system. Measures such as gastric lavage or the administration of activated charcoal are officially described for implementation soon after recent ingestion. Intensive medical monitoring is a required component of managing the acute event and preventing severe complications.

Therapeutic Uses of Trentilin

Quick Facts: Trentilin (Pentoxifylline)

  • Primary Indication: Used to manage symptoms associated with chronic occlusive peripheral arterial disease in the limbs.
  • Benefit: May assist in reducing certain signs and symptoms, such as the muscle pain or cramping experienced during exercise (intermittent claudication).

Trentilin (pentoxifylline) is approved for the symptomatic management of intermittent claudication. This condition is a sign of chronic occlusive arterial disease, typically affecting the lower extremities. The treatment may provide relief from discomfort, aching, and tiredness in the limbs associated with poor circulation. By addressing the impaired blood flow to the affected microcirculation, the medication aims to enhance tissue oxygenation and may improve the function of the limbs.

While this therapeutic option may help reduce the frequency and severity of claudication symptoms, it is not a replacement for more definitive interventions, such as surgical procedures or lifestyle modifications like exercise programs, when managing peripheral vascular disease. Trentilin is used as part of an overall treatment plan determined by a healthcare provider for patients with this condition. Individual response to the medication may vary, and the maximum therapeutic benefit may require a sustained period of use.

Eligibility and Restrictions for Use

Trentilin (pentoxifylline) is an authorized medication for adults, but official regulatory documents strictly define populations who must not use it (contraindications) or for whom its use is limited.

Contraindications (Must Not Use)

The medicine is strictly prohibited for individuals who meet the following criteria, based on documented risk:

  • Hypersensitivity: Patients with a known allergy or intolerance to pentoxifylline or other methylxanthine drugs (such as caffeine, theophylline, or theobromine).
  • Recent Hemorrhage: Individuals who have experienced recent bleeding in the brain (cerebral hemorrhage) or the eye (retinal hemorrhage).
  • Acute Cardiac Events: Some regulatory documents also contraindicate use in patients with acute myocardial infarction.

Eligibility Restrictions

Certain patient groups require caution, monitoring, or dose reduction due to the drug's metabolism and established safety profiles:

  • Pediatric Patients: Safety and effectiveness have not been established for patients under 18 years of age.
  • Organ Impairment: Patients with severe hepatic (liver) impairment or severe renal (kidney) impairment (Creatinine Clearance <30 mL/min) are generally advised against use, or require significant dose reduction and monitoring.
  • Pregnancy/Lactation: Use during pregnancy is classified as Category C (or similar cautionary language) and is only advised if the potential benefit outweighs the potential risk. Pentoxifylline passes into breast milk, requiring a decision to discontinue the drug or nursing.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Trentilin (pentoxifylline) is defined by officially documented risks of pharmacodynamic augmentation and pharmacokinetic alteration of drug exposure, as stated in regulatory documents.

Documented Pharmacodynamic Interactions

Co-administration with anticoagulants (such as Vitamin K antagonists) and platelet aggregation inhibitors is associated with an increased risk of bleeding and/or prolonged prothrombin time. A formal restriction requires that co-use with Ketorolac is contraindicated due to this documented risk. An additive effect has also been observed with antihypertensive drugs, which may enhance the hypotensive effect, and with oral hypoglycaemic agents, which may potentiate their blood sugar lowering action.

Documented Pharmacokinetic Interactions

Pentoxifylline's exposure can be increased by substances that inhibit its metabolic clearance. Strong CYP1A2 inhibitors (e.g., Ciprofloxacin) may increase plasma concentrations, as does Cimetidine. Conversely, Trentilin itself causes increased theophylline levels and the risk of toxicity when co-administered with theophylline-containing drugs. The regulatory profile also notes that food intake delays the time to peak plasma concentrations but does not affect overall drug absorption. Population-specific cautions state that hepatic or renal impairment officially results in increased exposure to the drug and its active metabolites.

Mechanism of Action

How Trentilin Works: Mechanism of Action

The mechanism of action for Pentoxifylline is characterized by the concurrent modulation of blood flow properties and inflammatory components within the microcirculation.

Molecular Action: Modulating Cellular Signaling

The drug functions as a nonselective inhibitor of Phosphodiesterase (PDE) enzymes, particularly PDE Type 4, found in blood cells. By blocking PDE, the drug prevents the breakdown of cyclic Adenosine Monophosphate (cAMP), increasing the sustained concentration of this critical intracellular messenger. This molecular action initiates a cascade that alters the structure and function of red and white blood cells.

Improving Blood Flow and Erythrocyte Flexibility

The increase in cellular cAMP leads to the hyper-phosphorylation of structural proteins within red blood cells (erythrocytes), enhancing their deformability (flexibility) . This modification, alongside a reduction in overall blood viscosity (thickness), facilitates the passage of red blood cells through narrowed capillaries. The resulting physiological effect is an improvement in microcirculatory flow, which influences tissue oxygenation dynamics.

Dampening Inflammatory Cell Adhesion

In white blood cells (leukocytes), the cAMP cascade suppresses the synthesis of major pro-inflammatory cytokines, such as Tumor Necrosis Factor-alpha (TNF-alpha), by modulating gene transcription factors. This anti-inflammatory mechanism modulates the activation and adhesion of white blood cells to the inner lining of blood vessels. This effect influences microvascular obstruction dynamics, impacting blood movement through the microvasculature.

Dosage and Administration Information

How Trentilin is Used

Trentilin (Pentoxifylline) is administered exclusively through the oral route using the 400 mg extended-release tablet formulation. The tablets are specifically designed to be swallowed whole and must not be crushed, chewed, or broken, as doing so would compromise the controlled-release properties of the medication.


Dosing and Contextual Timing

The typical initial adult dosing regimen involves taking 400 mg three times daily (TID), establishing the total daily maximum dose at 1200 mg. Proper administration requires taking each tablet with or immediately after a meal to help minimize potential gastrointestinal discomfort. The treatment pattern is sustained, and an administration duration of at least eight weeks is required before the full effect can be determined.


Administration Adjustments and Restrictions

If intolerance or adverse effects arise, the dosage may be adjusted downwards, often to 400 mg twice daily (BID), which serves as a common maintenance regimen. Dose reductions are also necessary for specific patient populations, particularly those with severe renal impairment (creatinine clearance below 30 mL/min) or severe hepatic impairment. For older adults, cautious dose selection is advised, often starting at the lower range. If a scheduled dose is missed, the standard practice is to skip the missed dose entirely and resume the normal schedule, without taking a double dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of Studies for Trentilin


Evidence for Use in Intermittent Claudication

Trentilin (pentoxifylline) was studied for patterns of change when intermittent claudication is present. Intermittent claudication is the muscle pain or cramping that arises from chronic occlusive peripheral arterial disease (PAD). The body of evidence for this condition is largely made up of numerous randomized, placebo-controlled clinical trials (RCTs). These RCTs were the primary approach used in research exploring how symptoms change over time. The key functional outcomes studies monitored involved measures of walking capacity. Specifically, research examined outcomes related to physical discomfort such as pain-free walking distance, which was studied for patterns of change. Studies also monitored physical measurements of the blood, including blood viscosity (thickness) and red blood cell flexibility. Findings describe patterns observed in the studies regarding walking capacity, with various trials reporting differing observations over the defined time intervals. Findings were mixed across the scientific literature, meaning the observations from one study did not always align perfectly with those from another.

Long-Term Research and Durability of Findings

The majority of the randomized controlled trials were of limited follow-up duration, typically running for less than six months. This means there is limited information for long-term outcomes when Trentilin was evaluated in studies lasting over multiple years. While some long-term observational data was studied for general patient utilization, long-term effects are not fully established regarding the durability of any observed changes in walking distance or blood properties. Furthermore, the initial research was not primarily designed to evaluate outcomes related to survival or major cardiovascular events. Therefore, comparative evidence is lacking from the main clinical trials concerning long-term survival or rates of amputation.

Understanding the Quality and Limitations of the Evidence

Scientific analysis of the overall evidence landscape points out several areas where the research quality varies across studies. Many of the older trials that formed the basis of the evidence sometimes lacked detailed reporting on their methodology. This can introduce uncertainty into the findings. The evidence base is often graded as having low to moderate certainty by independent scientific review bodies because of this variability and where findings were mixed across different trials. Research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted. It remains clear that evidence highlights what is known—and what is still uncertain—about Trentilin.

Frequently Asked Questions (FAQ)

Common questions about Trentilin (FAQ)


Q: What is Trentilin used for, exactly?

Official product information indicates that Trentilin is specifically used to manage the symptoms of intermittent claudication. This condition causes muscle pain or cramping in the legs due to chronic occlusive peripheral arterial disease (PAD). The medication is prescribed to support circulation in these patients.


Q: Is Trentilin a pain reliever or an anti-inflammatory drug?

The drug is officially categorized as a hemorrheologic agent, meaning its primary function is to modify the physical properties of blood flow. While its mechanism of action includes a role in dampening inflammatory cell adhesion, it is not officially classified as an analgesic or pain reliever.


Q: What are the main benefits of taking Trentilin?

Studies and official information indicate that the drug was primarily examined for its ability to increase pain-free walking distance in patients with intermittent claudication. The physiological effects include reducing overall blood viscosity (thickness) and improving red blood cell flexibility.


Q: Can Trentilin make you feel tired or dizzy?

According to the official product information, dizziness is listed as a common side effect of this medication. However, regulatory documents do not specifically list common terms for feeling generally tired or fatigued among the most frequently reported adverse reactions.


Q: Is it normal to have a slight headache when starting Trentilin?

Official regulatory documents indicate that headache is one of the most frequently reported side effects observed during clinical trials. Although the documents do not use the term 'normal' or 'expected,' this side effect is one of those most frequently reported.


Q: What is the expected time frame to notice changes from Trentilin?

According to official product information, the full effect of the medication can typically be determined after a duration of at least eight weeks of administration. The treatment course is designed to be sustained over this period to observe any potential changes.


Q: Is Trentilin considered a long-term treatment?

The official regimen is described as a sustained treatment pattern. While some patients may use the drug for extended periods, the primary clinical trials supporting its approval were generally of limited follow-up duration, meaning its full long-term outcomes and durability are not fully established in clinical trial data.


Q: How long does Trentilin stay in your system after the last dose?

Official product information notes that the drug undergoes extensive metabolism in the body, and its clearance is affected if a patient has renal (kidney) or hepatic (liver) impairment. Regulatory documents typically do not provide a simple, exact time for when the drug is completely cleared from the system.


Q: Does Trentilin interact with caffeine?

Official regulatory documents state that the drug is contraindicated (must not be used) if an individual has a known intolerance or allergy to methylxanthine derivatives. Because caffeine is a methylxanthine derivative, this information is included as a related cautionary note in the official warnings.


Q: Is Trentilin safe for older adults?

Caution is formally advised for use in older adults. Official regulatory documents recommend that dose selection for this population should be cautious, often starting at the lower end of the established dosing range, as cautious dose selection is advised for this population.


Q: Can Trentilin be used during pregnancy?

Use during pregnancy is classified under a cautionary category (such as Category C). Official regulatory documents indicate use should only be considered if the potential benefit to the mother is determined by the healthcare provider to outweigh the potential risk to the fetus.


Q: Can Trentilin be used while breastfeeding?

Official documents confirm that the drug passes into breast milk. The official guidance states that a decision should be made to either discontinue the use of the drug or discontinue nursing.


Q: What official clinical trials support the use of Trentilin?

The support for the drug is based on numerous randomized, placebo-controlled clinical trials (RCTs) that examined outcomes like changes in walking capacity. While official documents summarize the findings, they generally do not list the specific names or identifying numbers of individual trials.


Q: Can Trentilin affect blood pressure readings?

Yes, regulatory documents list hypotension (low blood pressure) as an officially documented adverse reaction. Furthermore, official text notes that there may be an additive blood pressure lowering effect when the drug is co-administered with certain antihypertensive drugs.


Q: Can Trentilin affect mental health or mood?

Officially listed adverse reactions under the Nervous System class include insomnia and tremor. The regulatory label does not specifically reference generalized or large-scale changes to mood or broader mental health in its adverse reaction list.


Q: Are there long-term risks associated with taking Trentilin for many years?

The primary clinical trials supporting the drug's use were generally of limited follow-up duration (less than six months). Because of this, official regulatory documents note that the drug's full long-term effects are not fully established based on the main body of research.


Q: Does Trentilin affect sleep patterns?

Official product information lists insomnia as an officially documented side effect under the Nervous System class. Insomnia is difficulty falling or staying asleep, which can impact a patient's overall sleep pattern.


Q: Does Trentilin work right away or does it build up over time?

The medication is designed as an extended-release tablet, meaning the active substance is released slowly over time to sustain the therapeutic effect. Consequently, a minimum of eight weeks is required to fully determine the effects of the treatment.


Q: Is there a specific time of day Trentilin is usually taken?

Regulatory guidance states the drug is typically taken three times daily. The guidance is to take the drug along with food.


Q: Does Trentilin interact with common over-the-counter pain relievers?

Official documents note that co-administering the drug with platelet aggregation inhibitors (a drug class that includes some common pain relievers) is associated with an increased risk of bleeding. Ketorolac is also explicitly prohibited due to a documented risk.


Q: Are there any dietary restrictions when using Trentilin?

Regulatory documents state that food intake delays the time to peak plasma concentrations of the drug in the body. However, no specific dietary restriction or food is officially listed as prohibited in the product information, although food intake is noted to delay peak concentration.


Q: Is Trentilin an antibiotic?

No, Trentilin is not an antibiotic. The drug is officially categorized as a hemorrheologic agent and a methylxanthine derivative, which means it works by modifying blood flow properties.


Q: If I miss a dose of Trentilin, does it ruin the whole treatment effect?

The official instruction for a missed dose is to skip that dose entirely and resume the drug's normal schedule, without taking a double dose. The regulatory instruction to skip the missed dose and resume the normal schedule is consistent with the drug’s long-term, sustained treatment pattern.


Q: Why is Trentilin sometimes described as a 'pro-drug'?

The active ingredient is metabolized in the body into compounds called active metabolites, which contribute significantly to its therapeutic effect. This process, combined with its action as a Phosphodiesterase (PDE) inhibitor, explains why the drug's full effect relies on how the body processes it.


Q: Is there scientific evidence that Trentilin helps with circulation issues?

Yes, the medication is officially indicated for symptoms of intermittent claudication, a condition directly caused by a type of circulatory issue called peripheral arterial disease (PAD). Its function as a hemorrheologic agent is supported by evidence related to improving microcirculation.


Q: Does Trentilin require a special prescription?

Yes, official product information clearly categorizes Trentilin as a prescription medicine. It is not available for purchase over-the-counter and requires a valid prescription from a licensed healthcare professional.


Q: Why do some people say Trentilin did not work for them?

Scientific analysis of the evidence notes that findings were mixed across different clinical trials regarding efficacy outcomes. This inherent variability in study results provides the regulatory basis for understanding why individual patient responses to the medication may vary.


Q: Is the benefit of Trentilin proven by strong evidence?

Independent scientific review bodies often grade the evidence base for the drug as having low to moderate certainty. This is because the findings were mixed across different trials and there was variability in the methodology of the studies that formed the evidence base.

How should Trentilin be stored and disposed of?

How to Store and Dispose of Trentilin (Pentoxifylline)

To ensure product stability, Trentilin must be stored according to official regulatory requirements. The tablets should be kept at controlled room temperature, typically between 15 C to 30 C (59 F to 86 F), with some labels advising against storage above 25 C.


Storage and Handling

  • Protection: The medicine must be protected from light, moisture, and excessive heat. It should be kept in its original package or container.
  • Child Safety: It is mandatory to keep Trentilin out of the sight and reach of children.
  • Prohibited: Keep the product from freezing.

Disposal Instructions

Do not throw away unused or expired Trentilin in household trash or wastewater. Patients are instructed to ask a pharmacist about proper disposal or to utilize an authorized drug take-back location. If no take-back program is available, the drug may be mixed with an undesirable substance (such as dirt) and sealed before discarding in the trash, according to official guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trentilin found in:

A-Z Index: